An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan® RC Early Analysis Review (CLEAR) trial

An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan® RC Early Analysis Review (CLEAR) trial

Bibliographic Details
Main Authors:	Crichton, Andrew C, Nixon, Donald R, Simonyi, Susan, Bhogal, Meetu, Sigouin, Christopher S, Discepola, Marino J, Hutnik, Cindy ML, Baptiste, Darryl C, Yan, David B
Format:	Online
Language:	English
Published:	Dove Medical Press 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043802/

Similar Items

An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
by: Nixon, Donald R, et al.
Published: (2012)

Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study
by: Chen, Ying Ying, et al.
Published: (2016)

Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting
by: Park, Ki Ho, et al.
Published: (2014)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
by: Day, Douglas G, et al.
Published: (2013)

Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure
by: Tung, Jonathan D, et al.
Published: (2012)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
by: Chang-Lin, Joan-En, et al.
Published: (2011)

Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol
by: Fang, Yuan, et al.
Published: (2015)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
by: Pfennigsdorf, Stefan, et al.
Published: (2012)

Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial
by: DuBiner, Harvey B, et al.
Published: (2014)

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
by: Stevens, Annemie, et al.
Published: (2016)

Aqueous misdirection syndrome: an interesting case presentation
by: Moinul, Prima, et al.
Published: (2015)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Published: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Published: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
by: Tsumura, Toyoaki, et al.
Published: (2012)

Diurnal Intraocular Pressure with Bimatoprost/Timolol Fixed Combination versus Latanoprost/Timolol Fixed Combination in Healthy Subjects
by: Shim, Seong Hee, et al.
Published: (2014)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
by: Shafiee, Afshin, et al.
Published: (2013)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
by: Myers, Jonathan S, et al.
Published: (2014)

An Effect of Bimatoprost: Adverse for Some, Therapeutic for Others
by: Dubey, Ashok Kumar
Published: (2011)

Bimatoprost in the Treatment of Eyelash Universalis Alopecia Areata
by: Vila, Teresa Ojeda, et al.
Published: (2010)

The biodisposition and hypertrichotic effects of bimatoprost in mouse skin
by: Woodward, David F, et al.
Published: (2013)

Periorbital muscle atrophy associated with topical bimatoprost therapy
by: Wang, Priscilla Xinhui, et al.
Published: (2014)

Tear biomarkers in latanoprost and bimatoprost treated eyes.
by: Shweta Reddy, et al.

Hirsutism following the use of bimatoprost eyedrops for glaucoma
by: Kaliaperumal, Subashini, et al.
Published: (2014)

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
by: Wang, Kaidi, et al.
Published: (2014)

Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon
by: Shen, Jie, et al.
Published: (2016)

Evaluating the Biostability of Yellow and Clear Intraocular Lenses with a System Simulating Natural Intraocular Environment
by: Hayashi, Rijo, et al.
Published: (2016)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
by: Shen J, et al.
Published: (2018-08-01)

Efficacy of various antioxidants in the protection of the retinal pigment epithelium from oxidative stress
by: Kagan, Dov B, et al.
Published: (2012)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
by: Inoue, Kenji, et al.
Published: (2012)

The Role of Bimatoprost Eyelash Gel in Chemotherapy-induced Madarosis: An Analysis of Efficacy and Safety
by: Morris, Carrie L, et al.
Published: (2011)

Bimatoprost for Eyelash Growth in Japanese Subjects: Two Multicenter Controlled Studies
by: Harii, K., et al.
Published: (2014)

Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
by: Chen, Wensheng, et al.
Published: (2014)

Effects of Latanoprost and Bimatoprost on the Expression of Molecules Relevant to Ocular Inflow and Outflow Pathways
by: Li, Xiaohong, et al.
Published: (2016)

Bimatoprost Induced Serous Macular Detachment after Cataract Surgery
by: Parchand, Swapnil, et al.
Published: (2016)

Erratum to: Bimatoprost for Eyelash Growth in Japanese Subjects: Two Multicenter Controlled Studies
by: Harii, K., et al.
Published: (2014)

An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
by: Borchert, Mark, et al.
Published: (2016)

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
by: Imasawa, Mitsuhiro, et al.
Published: (2016)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
by: Campbell, Joanna H, et al.
Published: (2014)

Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial
by: Oddone, Francesco, et al.
Published: (2015)

RC circuit response
by: Arshad, Atika, et al.
Published: (2011)